PriceTargets.com logo

NeuroSense Therapeutics - NRSN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $14.00
  • Forecasted Upside: 1,066.67%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 2 Strong Buy Ratings
$1.20 As of 12/4/2025 05:00 PM ET
▼ -0.03 (-2.44%)

This chart shows the closing price for NRSN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NeuroSense Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NRSN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NRSN

Analyst Price Target is $14.00
▲ +1,066.67% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for NeuroSense Therapeutics in the last 3 months. The average price target is $14.00, with a high forecast of $14.00 and a low forecast of $14.00. The average price target represents a 1,066.67% upside from the last price of $1.20.

This chart shows the closing price for NRSN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 investment analysts is to moderate buy stock in NeuroSense Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 2 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 2 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 2 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/24/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$14.00
11/19/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/13/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/15/2025Zacks ResearchUpgradeHold
10/14/2025Noble FinancialUpgradeStrong-Buy
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/15/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$14.00
7/10/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$14.00
5/12/2025D Boral CapitalUpgradeStrong-Buy
5/12/2025D. Boral CapitalInitiated CoverageBuy$14.00
12/16/2024Maxim GroupReiterated RatingBuy ➝ Hold
7/17/2023Alliance Global PartnersInitiated CoverageBuy
1/7/2022Maxim GroupInitiated CoverageBuy$7.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

NeuroSense Therapeutics logo
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Read More

Today's Range

Now: $1.20
Low: $1.15
High: $1.24

50 Day Range

MA: $1.14
Low: $0.92
High: $1.25

52 Week Range

Now: $1.20
Low: $0.81
High: $2.60

Volume

241,903 shs

Average Volume

378,950 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of NeuroSense Therapeutics?

The following Wall Street analysts have issued research reports on NeuroSense Therapeutics in the last twelve months: D Boral Capital, D. Boral Capital, Maxim Group, Noble Financial, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for NRSN.

What is the current price target for NeuroSense Therapeutics?

0 Wall Street analysts have set twelve-month price targets for NeuroSense Therapeutics in the last year. Their average twelve-month price target is $14.00, suggesting a possible upside of 1,066.7%. D. Boral Capital has the highest price target set, predicting NRSN will reach $14.00 in the next twelve months. D. Boral Capital has the lowest price target set, forecasting a price of $14.00 for NeuroSense Therapeutics in the next year.
View the latest price targets for NRSN.

What is the current consensus analyst rating for NeuroSense Therapeutics?

NeuroSense Therapeutics currently has 1 sell rating, 2 hold ratings, 1 buy rating and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NRSN.

What other companies compete with NeuroSense Therapeutics?

Other companies that are similar to NeuroSense Therapeutics include 180 Life Sciences, 4D pharma, Ainos, Alvotech and Aravive. Learn More about companies similar to NeuroSense Therapeutics.

How do I contact NeuroSense Therapeutics' investor relations team?

The company's listed phone number is 972-9799-6183. The official website for NeuroSense Therapeutics is www.neurosense-tx.com. Learn More about contacing NeuroSense Therapeutics investor relations.